Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly-diagnosed patients: impact and outcome

Authors :: Gill, Harinder
Raghupathy, Radha
Hou, Hsin-An
Cheng-Hong Tsai, Xavier
Tantiworawit, Adisak
Ooi, Melissa G.
Gan, Gin-Gin
Wong, Chieh-Lee
Yim, Rita
Chin, Lynn
Lee, Paul
Li, Vivian W.K.
Au, Lester
Zhang, Qi
Leung, Garret M.K.
Wu, Tony K.Y.
Lee, Carmen Y.Y.
Chng, Wee-Joo
Tien, Hwei-Fang
Kumana, Cyrus R.
Kwong., Yok-Lam
Source :: Blood Advances; 20240101, Issue: Preprints
Publication Year :: 2024
Abstract: •In APL, frontline oral or intravenous arsenic trioxide (ATO) reduced early deaths and improved RFS and OS, independent of risk category.•Without frontline ATO, inferior RFS could still be mitigated by using an oral-ATO-based regimen in maintenance.

Full Text Access

Tools